Trial Profile
Bortezomib, pegylated liposomal doxorubicin and dexamethasone as induction therapy prior to ASCT (autologous stem cell transplantation) with reduced intensity in elderly patients with multiple myeloma [Bortezomib, Desametasone e Doxorubicina liposomiale peghilata come terapia di induzione prima di ASCT (autologous stem cell transplantation) ad intensita ridotta in pazienti anziani affetti da mieloma multiplo]
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Acronyms PAD-PEG
- 27 Jun 2011 New trial record